Barclays Maintains Overweight on AbbVie, Lowers Price Target to $187
AbbVie, Inc. +1.19% Pre
AbbVie, Inc. ABBV | 188.76 188.76 | +1.19% 0.00% Pre |
Barclays analyst Carter Gould maintains AbbVie (NYSE:
ABBV) with a Overweight and lowers the price target from $195 to $187.